Market Overview

Waters Corporation (NYSE: WAT) Reports Second Quarter 2018 Financial Results

Share:
  • Sales of $596 million grew 7% as reported and 5% in constant
    currency
  • Growth across all end markets with strong TA performance
  • Strong growth from China, partially offset by softness in the U.S.
  • GAAP EPS increased 21% to $1.98; non-GAAP EPS increased 11% to $1.95

Waters Corporation (NYSE:WAT) today announced second quarter
2018 sales of $596 million, a 7% increase as reported, versus sales of
$558 million for the second quarter of 2017. Foreign currency
translation increased sales growth by approximately 2% for the quarter.

On a GAAP basis, diluted earnings per share (EPS) for the second quarter
increased 21% to $1.98, compared to $1.63 for the second quarter of
2017. On a non-GAAP basis, EPS for the second quarter increased 11% to
$1.95, compared to $1.76 for the second quarter of 2017. A description
and reconciliation of GAAP to non-GAAP results appear in the table below
and can be found on the Company's website at http://www.waters.com
under the caption "Investors."

On a GAAP basis, net cash provided by operating activities for the
second quarter of 2018 decreased to $101 million from $177 million for
the second quarter of 2017. On a non-GAAP basis, adjusted free cash flow
decreased to $144 million from $159 million for the second quarter of
2017.

For the first half of 2018, the Company's sales were $1,127 million, up
7% as reported, compared with sales of $1,056 million in the first half
of 2017. Foreign currency translation increased sales growth by
approximately 4% during the first half of 2018. On a GAAP basis, EPS for
the first half of 2018 was up 15% to $3.39, compared to $2.94 for the
first half of 2017. On a non-GAAP basis and including adjustments in the
attached reconciliation, EPS increased 10% to $3.54 in 2018 as compared
to $3.22 for the first half of 2017. On a GAAP basis, net cash provided
by operating activities for the first half of 2018 decreased to $277
million from $351 million for the first half of 2017. On a non-GAAP
basis, adjusted free cash flow decreased to $304 million from $316
million for the first half of 2017.

Commenting on the Company's performance, Chris O'Connell, Chairman and
Chief Executive Officer, said, "We are pleased that we saw sequential
improvement in our second quarter results, highlighted by strong growth
in China, our TA product line, and our recurring revenues. In addition,
we delivered meaningful operating leverage, which enabled us to achieve
double-digit earnings per share growth. Our second quarter results give
us confidence in the ongoing growth trajectory of our business."

Unless otherwise noted, sales growth and decline percentages are
presented on an as reported basis and are the same as the sales growth
and decline percentages presented on a constant currency basis, as
compared with the same period in the prior year, each of which is
detailed in the reconciliation of sales growth rates to constant
currency growth rates found below.

During the second quarter of 2018, sales into the pharmaceutical market
grew 6% as reported and 4% in constant currency, sales into the
industrial market grew 5% as reported and 3% in constant currency, and
sales into the governmental and academic markets grew 16% as reported
and 13% in constant currency. During the first half of 2018, sales into
the pharmaceutical market grew 7% as reported and 4% in constant
currency, sales into the industrial market grew 3% as reported and were
flat in constant currency, and sales into the governmental and academic
markets grew 13% as reported and 10% in constant currency.

During the second quarter, recurring revenues, which represent the
combination of service and precision chemistries revenues, grew 11% as
reported and 8% in constant currency, while instrument system sales grew
3% as reported and 2% in constant currency. For the first half of 2018,
recurring revenues grew 11% as reported and 7% in constant currency,
while instrument system sales grew 2% as reported and were flat in
constant currency.

Geographically, sales in Asia during the quarter grew 10% as reported
and 8% in constant currency, sales in Europe grew 10% as reported and 5%
in constant currency, and sales in the Americas grew 1%, while U.S.
sales declined 2%. For the first half of 2018, sales in Asia grew 6% as
reported and 4% in constant currency, sales in Europe grew 13% as
reported and 4% in constant currency, and sales in the Americas grew 2%,
with U.S. sales also growing 2%.

Third Quarter and Fiscal Year 2018 Financial Outlook

Waters Corporation expects third quarter 2018 constant currency sales
growth to be in a range of 4% to 6%, and, as of today, currency
translation is expected to decrease third quarter sales growth by
approximately 1% to 2%. The Company also expects third quarter 2018
non-GAAP earnings per fully diluted share to be in the range of $1.85 to
$1.95. Please refer to the table below for a reconciliation of the
projected GAAP to non-GAAP financial outlook for the third quarter.

The Company maintains its full-year 2018 guidance for constant currency
sales growth in the range of 4% to 6%. As of today, currency translation
is expected to increase 2018 sales growth by less than 1%. The Company
is revising its guidance for full-year 2018 non-GAAP earnings per fully
diluted share to the range of $8.05 to $8.20, from the prior guidance
range of $8.10 to $8.30. Please refer to the table below for a
reconciliation of the projected GAAP to non-GAAP financial outlook for
the full year.

Conference Call

Waters Corporation will webcast its second quarter 2018 financial
results conference call today, July 24, 2018 at 8:00 a.m. Eastern Time.
To listen to the call, please visit www.waters.com,
choose "Investors," and click on the "Live Webcast." A replay will be
available through July 31, 2018 at midnight Eastern Time on the same
website by webcast and also by phone at 402-661-5143.

About Waters Corporation

Waters Corporation (NYSE:WAT), the world's leading specialty
measurement company, has pioneered chromatography, mass spectrometry and
thermal analysis innovations serving the life, materials and food
sciences for nearly 60 years. With approximately 7,000 employees
worldwide, Waters operates directly in 31 countries, including 15
manufacturing facilities, with products available in more than 100
countries. For more information, visit www.waters.com.

Non-GAAP Financial Measures

This press release contains financial measures, such as constant
currency growth rate, adjusted operating income, adjusted net income,
adjusted earnings per diluted share and free cash flow, among others,
which are considered "non-GAAP" financial measures under applicable U.S.
Securities and Exchange Commission rules and regulations. These non-GAAP
financial measures should be considered supplemental to, and not a
substitute for, financial information prepared in accordance with
generally accepted accounting principles (GAAP). The Company's
definition of these non-GAAP measures may differ from similarly titled
measures used by others. The non-GAAP financial measures used in this
press release adjust for specified items that can be highly variable or
difficult to predict. The Company generally uses these non-GAAP
financial measures to facilitate management's financial and operational
decision-making, including evaluation of Waters Corporation's historical
operating results, comparison to competitors' operating results and
determination of management incentive compensation. These non-GAAP
financial measures reflect an additional way of viewing aspects of the
Company's operations that, when viewed with GAAP results and the
reconciliations to corresponding GAAP financial measures, may provide a
more complete understanding of factors and trends affecting Waters
Corporation's business. Because non-GAAP financial measures exclude the
effect of items that will increase or decrease the Company's reported
results of operations, management strongly encourages investors to
review the Company's consolidated financial statements and publicly
filed reports in their entirety. Reconciliations of the non-GAAP
financial measures to the most directly comparable GAAP financial
measures are included in the tables accompanying this release.

Cautionary Statement

This release may contain "forward-looking" statements regarding future
results and events. For this purpose, any statements that are not
statements of historical fact may be deemed forward-looking statements.
Without limiting the foregoing, the words, "feels", "believes",
"anticipates", "plans", "expects", "intends", "suggests", "appears",
"estimates", "projects", and similar expressions, whether in the
negative or affirmative, are intended to identify forward-looking
statements. The Company's actual future results may differ significantly
from the results discussed in the forward-looking statements within this
release for a variety of reasons, including and without limitation,
foreign exchange rate fluctuations potentially affecting translation of
the Company's future non-U.S. operating results; the impact on demand
for the Company's products among the Company's various market sectors
from economic, sovereign and political uncertainties; the effect on the
Company's financial results from the United Kingdom voting to exit the
European Union; fluctuations in expenditures by the Company's customers,
in particular large pharmaceutical companies; introduction of competing
products by other companies and loss of market share; pressures on
prices from competitors and/or customers; regulatory, economic and
competitive obstacles to new product introductions; other changes in
demand for the Company's products from the effect of mergers and
acquisitions by the Company's customers; increased regulatory burdens as
the Company's business evolves, especially with respect to the U.S. Food
and Drug Administration and U.S. Environmental Protection Agency, among
others; impact of the newly enacted tax reform legislation in the U.S.;
shifts in taxable income in jurisdictions with different effective tax
rates; the outcome of tax examinations or changes in respective country
legislation affecting the Company's effective tax rate; the effect of
the adoption of new accounting standards; the ability to access capital,
maintain liquidity and service the Company's debt in volatile market
conditions, particularly in the U.S., as a large portion of the
Company's cash is held and operating cash flows are generated outside
the U.S.; environmental and logistical obstacles affecting the
distribution of products and risks associated with lawsuits and other
legal actions, particularly involving claims for infringement of patents
and other intellectual property rights. Such factors and others are
discussed more fully in the sections entitled "Forward-Looking
Statements" and "Risk Factors" of the Company's annual report on Form
10-K for the year ended December 31, 2017 as filed with the Securities
and Exchange Commission, which "Forward-Looking Statements" and "Risk
Factors" discussions are incorporated by reference in this release. The
forward-looking statements included in this release represent the
Company's estimates or views as of the date of this release and should
not be relied upon as representing the Company's estimates or views as
of any date subsequent to the date of this release.

 
Waters Corporation and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
       
 
Three Months Ended Six Months Ended
June 30, 2018 July 1, 2017 June 30, 2018 July 1, 2017
 
Net sales $ 596,219 $ 558,250 $ 1,126,889 $ 1,056,219
 
Costs and operating expenses:
Cost of sales 243,135 229,627 464,556 440,722
Selling and administrative expenses 136,645 130,093 267,052 260,766
Research and development expenses 35,644 32,937 70,124 63,689
Litigation provision (settlement) - 10,018 (1,672 ) 10,018
Purchased intangibles amortization 1,602 1,693 3,261 3,422
Acquired in-process research and development - - - 5,000
 
Operating income 179,193 153,882 323,568 272,602
 
Other (expense) income* (1,828 ) (97 ) (1,482 ) 52
Interest expense, net (2,804 ) (5,713 ) (6,976 ) (11,095 )
 
Income from operations before income taxes 174,561 148,072 315,110 261,559
 
Provision for income taxes** 18,884 16,250 47,482 24,180
 
Net income $ 155,677 $ 131,822 $ 267,628 $ 237,379
 
 
Net income per basic common share $ 2.00 $ 1.65 $ 3.42 $ 2.97
 
Weighted-average number of basic common shares 77,833 79,979 78,330 80,029
 
 
Net income per diluted common share $ 1.98 $ 1.63 $ 3.39 $ 2.94
 
Weighted-average number of diluted common shares and equivalents 78,438 80,756 79,041 80,769

 

* The Company adopted new accounting guidance which requires that an
employer disaggregate the service cost component from other components
of net benefit cost. As a result of the adoption of this standard, the
components of net periodic benefit cost other than the service cost
component are included in other (expense) income in the consolidated
statements of operations and all previous periods have been adjusted
accordingly.

** The provision for income taxes for the three and six months ended
June 30, 2018 includes a $9 million benefit and a $4 million expense,
respectively, related to the tax on the change in foreign currency
exchange rates on the earnings taxed on December 31, 2017 under the Tax
Cuts and Jobs Act. The difference is due to the change from the foreign
currency exchange rates required by the U.S. Department of the Treasury
on December 31, 2017 to the foreign currency exchange rates on either
the date of distribution of assets into the U.S. or the foreign currency
exchange rates as of June 30, 2018.

         
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segment, Products & Services, Geography
and Markets
Three Months Ended June 30, 2018 and July 1, 2017
(In thousands)
 
Current
Period Constant
Three Months Ended Percent Currency Currency
June 30, 2018 July 1, 2017 Change Impact Growth Rate (a)
 
NET SALES - OPERATING SEGMENT
 
Waters $ 527,305 $ 497,780 6% $ 10,067 4%
TA 68,914 60,470 14% 1,217 12%
           
Total $ 596,219 $ 558,250 7% $ 11,284 5%
 
 
NET SALES - PRODUCTS & SERVICES
 
Instruments $ 289,740 $ 282,014 3% $ 3,349 2%
 
Service 207,350 185,412 12% 5,391 9%
Chemistry   99,129   90,824 9%   2,544 6%
Total Recurring 306,479 276,236 11% 7,935 8%
           
Total $ 596,219 $ 558,250 7% $ 11,284 5%
 
 
NET SALES - GEOGRAPHY
 
Asia $ 236,905 $ 215,703 10% $ 3,285 8%
Americas 198,126 196,586 1% 299 1%
Europe 161,188 145,961 10% 7,700 5%
           
Total $ 596,219 $ 558,250 7% $ 11,284 5%
 
 
NET SALES - MARKETS
 
Pharmaceutical $ 338,354 $ 319,650 6% $ 6,228 4%
Industrial 183,664 174,531 5% 3,078 3%
Governmental & Academic 74,201 64,069 16% 1,978 13%
           
Total $ 596,219 $ 558,250 7% $ 11,284 5%
 
     
(a)   The Company believes that referring to comparable constant currency
growth rates is a useful way to evaluate the underlying performance
of Waters Corporation's net sales. Constant currency growth rate, a
non-GAAP financial measure, measures the change in net sales between
current and prior year periods, ignoring the impact of foreign
currency exchange rates during the current period. See description
of non-GAAP financial measures contained in this release.
 
           
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segment, Products & Services, Geography
and Markets
Six Months Ended June 30, 2018 and July 1, 2017
(In thousands)
   
Current
Period Constant
Six Months Ended Percent Currency Currency
June 30, 2018 July 1, 2017 Change Impact Growth Rate (a)
 
NET SALES - OPERATING SEGMENT
 
Waters $ 998,451 $ 941,206 6% $ 32,218 3%
TA 128,438 115,013 12% 2,932 9%
           
Total $ 1,126,889 $ 1,056,219 7% $ 35,150 3%
 
 
NET SALES - PRODUCTS & SERVICES
 
Instruments $ 530,147 $ 518,407 2% $ 13,050 -
 
Service 398,903 359,085 11% 14,755 7%
Chemistry   197,839   178,727 11%   7,345 7%
Total Recurring 596,742 537,812 11% 22,100 7%
           
Total $ 1,126,889 $ 1,056,219 7% $ 35,150 3%
 
 
NET SALES - GEOGRAPHY
 
Asia $ 437,185 $ 410,809 6% $ 9,374 4%
Americas 379,836 371,236 2% 717 2%
Europe 309,868 274,174 13% 25,059 4%
           
Total $ 1,126,889 $ 1,056,219 7% $ 35,150 3%
 
 
NET SALES - MARKETS
 
Pharmaceutical $ 643,682 $ 599,460 7% $ 22,013 4%
Industrial 345,994 335,834 3% 9,198 -
Governmental & Academic 137,213 120,925 13% 3,939 10%
           
Total $ 1,126,889 $ 1,056,219 7% $ 35,150 3%
 
       
(a)   The Company believes that referring to comparable constant currency
growth rates is a useful way to evaluate the underlying performance
of Waters Corporation's net sales. Constant currency growth rate, a
non-GAAP financial measure, measures the change in net sales between
current and prior year periods, ignoring the impact of foreign
currency exchange rates during the current period. See description
of non-GAAP financial measures contained in this release.
 
                       
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP Financials
Quarters and Six Months Ended June 30, 2018 and July 1, 2017
(In thousands, except per share data)
 
Income from
Operations
Selling & Research & Operating Other before Provision for Diluted
Administrative Development Operating Income (Expense) Income Income Net Earnings
Expenses(a)   Expenses(a)   Income Percentage   Income Taxes Taxes Income per Share
Quarter Ended June 30, 2018
GAAP $ 138,247 $ 35,644 $ 179,193 30.1% $ (1,828) $ 174,561 $ 18,884 $ 155,677 $ 1.98
Adjustments:
Purchased intangibles amortization (b) (1,602) - 1,602 0.3% - 1,602 304 1,298 0.02
Restructuring costs and certain other items (c) (1,189) - 1,189 0.2% - 1,189 260 929 0.01
Pension termination (d) - - - - 2,165 2,165 520 1,645 0.02
Tax reform (h) - - - - - - 8,573 (8,573) (0.11)
Certain income tax items (e)   -   -   -   -   -   -   (1,993)   1,993   0.03
Adjusted Non-GAAP $ 135,456 $ 35,644 $ 181,984   30.5% $ 337 $ 179,517 $ 26,548 $ 152,969 $ 1.95
 
Quarter Ended July 1, 2017
GAAP $ 141,804 $ 32,937 $ 153,882 27.6% $ (97) $ 148,072 $ 16,250 $ 131,822 $ 1.63
Adjustments:
Purchased intangibles amortization (b) (1,693) - 1,693 0.3% - 1,693 449 1,244 0.02
Restructuring costs and certain other items (c) (1,663) - 1,663 0.3% - 1,663 735 928 0.01
Litigation provisions (f) (10,018) - 10,018 1.8% 10,018 3,757 6,261 0.08
Certain income tax items (e)   -   -   -   -   -   -   (1,972)   1,972   0.02
Adjusted Non-GAAP $ 128,430 $ 32,937 $ 167,256   30.0% $ (97) $ 161,446 $ 19,219 $ 142,227 $ 1.76
 
Six Months Ended June 30, 2018
GAAP $ 268,641 $ 70,124 $ 323,568 28.7% $ (1,482) $ 315,110 $ 47,482 $ 267,628 $ 3.39
Adjustments:
Purchased intangibles amortization (b) (3,261) - 3,261 0.3% - 3,261 506 2,755 0.03
Restructuring costs and certain other items (c) (1,757) - 1,757 0.2% - 1,757 392 1,365 0.02
Pension termination (d) - - - - 2,165 2,165 520 1,645 0.02
Litigation settlement (f) 1,672 - (1,672) (0.1%) - (1,672) (401) (1,271) (0.02)
Stock award modification (g) (1,014) - 1,014 0.1% - 1,014 243 771 0.01
Tax reform (h) - - - - - - (3,877) 3,877 0.05
Certain income tax items (e)   -   -   -   -   -   -   (2,685)   2,685   0.03
Adjusted Non-GAAP $ 264,281 $ 70,124 $ 327,928   29.1% $ 683 $ 321,635 $ 42,180 $ 279,455 $ 3.54
 
Six Months Ended July 1, 2017
GAAP $ 274,206 $ 68,689 $ 272,602 25.8% $ 52 $ 261,559 $ 24,180 $ 237,379 $ 2.94
Adjustments:
Purchased intangibles amortization (b) (3,422) - 3,422 0.3% - 3,422 922 2,500 0.03
Restructuring costs and certain other items (c) (11,011) - 11,011 1.0% - 11,011 3,794 7,217 0.09
Litigation provisions (f) (10,018) - 10,018 0.9% - 10,018 3,757 6,261 0.08
Acquired in-process research and development (i) - (5,000) 5,000 0.5% - 5,000 962 4,038 0.05
Certain income tax items (e)   -   -   -   -   -   -   (2,447)   2,447   0.03
Adjusted Non-GAAP $ 249,755 $ 63,689 $ 302,053   28.6% $ 52 $ 291,010 $ 31,168 $ 259,842 $ 3.22
       
(a)   Selling & administrative expenses include purchased intangibles
amortization and litigation provisions. Research & development
expenses include acquired in-process research and development.
(b) The purchased intangibles amortization, a non-cash expense, was
excluded to be consistent with how management evaluates the
performance of its core business against historical operating
results and the operating results of competitors over periods of
time.
(c) Restructuring costs and certain other items were excluded as the
Company believes that the cost to consolidate operations and reduce
overhead and certain other income or expense items are not normal
and do not represent future ongoing business expenses of a specific
function or geographic location of the Company.
(d) The pension expense associated with terminating a frozen defined
benefit pension plan was excluded as the Company believes these
expenses are not indicative of normal operating costs.
(e) Certain income tax items were excluded as these non-cash expenses
and benefits represent updates in management's assessment of ongoing
examinations or other tax items that are not indicative of the
Company's normal or future income tax expense.
(f) Litigation provisions and settlement gain were excluded as these
costs are isolated, unpredictable and not expected to recur
regularly.
(g) The non-cash expense associated with accelerating the vesting of
certain stock awards was excluded as the Company believes these
expenses are not indicative of normal operating costs.
(h) The provision for income taxes for the three and six months ended
June 30, 2018 includes a $9 million benefit and a $4 million
expense, respectively, related to the tax on the change in foreign
currency exchange rates on the earnings taxed on December 31, 2017
under the Tax Cuts and Jobs Act. The difference is due to the change
from the foreign currency exchange rates required by the U.S.
Department of the Treasury on December 31, 2017 to the foreign
currency exchange rates on either the date of distribution of assets
into the U.S. or the foreign currency exchange rates as of June 30,
2018. The impact of the tax on the change in foreign currency
exchange rates was excluded as the Company believes this expense is
not indicative of the Company's normal or future income tax expense.
(i) Acquired In-Process Research and Development was excluded as it
relates to milestone payments associated with a licensing
arrangement for mass spectrometry that the Company believes is
unusual and not indicative of its normal business operations.
 
   
Waters Corporation and Subsidiaries
Preliminary Condensed Unclassified Consolidated Balance Sheets
(In thousands and unaudited)
 
 
 
June 30, 2018 December 31, 2017
 
Cash, cash equivalents and investments $ 2,248,493 $ 3,393,701
Accounts receivable 492,826 533,825
Inventories 299,595 270,294
Property, plant and equipment, net 335,709 349,278
Intangible assets, net 218,175 228,395
Goodwill 357,507 359,819
Other assets 205,439 189,042
Total assets $ 4,157,744 $ 5,324,354
 
 
Notes payable and debt $ 1,148,450 $ 1,997,774
Other liabilities 1,034,200 1,092,792
Total liabilities 2,182,650 3,090,566
 
Total equity 1,975,094 2,233,788
Total liabilities and equity $ 4,157,744 $ 5,324,354
 
 
Waters Corporation and Subsidiaries
Preliminary Condensed Consolidated Statements of Cash Flows
Three and Six Months Ended June 30, 2018 and July 1, 2017
(In thousands and unaudited)
             
Three Months Ended Six Months Ended
June 30, 2018 July 1, 2017 June 30, 2018 July 1, 2017
 
Cash flows from operating activities:
Net income $ 155,677 $ 131,822 $ 267,628 $ 237,379
Adjustments to reconcile net income to net cash
provided by operating activities:
Stock-based compensation 9,079 9,139 18,971 17,794
Depreciation and amortization 27,196 29,455 55,836 52,405
Change in operating assets and liabilities, net   (91,236 )   6,635     (65,878 )   43,682  
Net cash provided by operating activities 100,716 177,051 276,557 351,260
 
Cash flows from investing activities:
Additions to property, plant, equipment
and software capitalization (20,839 ) (17,647 ) (36,831 ) (35,358 )
Investment in unaffiliated company - - (3,215 ) (7,000 )
Payments for intellectual property licenses - (5,000 ) - (5,000 )
Net change in investments   331,382     (174,156 )   1,246,428     (246,494 )
Net cash provided by (used in) investing activities 310,543 (196,803 ) 1,206,382 (293,852 )
 
Cash flows from financing activities:
Net change in debt (99,855 ) 44,948 (849,774 ) 84,936
Proceeds from stock plans 10,558 19,923 34,845 58,182
Purchases of treasury shares (270,774 ) (76,661 ) (553,144 ) (165,834 )
Other cash flow from financing activities, net   (4,095 )   1,868     (2,158 )   430  
Net cash used in financing activities (364,166 ) (9,922 ) (1,370,231 ) (22,286 )
 
Effect of exchange rate changes on cash and cash equivalents   (21,411 )   12,485     (12,823 )   26,502  
Increase in cash and cash equivalents 25,682 (17,189 ) 99,885 61,624
 
Cash and cash equivalents at beginning of period   716,522     584,444     642,319     505,631  
Cash and cash equivalents at end of period $ 742,204   $ 567,255   $ 742,204   $ 567,255  
 
 
 
 
Reconciliation of GAAP Cash Flows from Operating Activities to
Free Cash Flow
(a)
 
 
 
Net cash provided by operating activities - GAAP $ 100,716 $ 177,051 $ 276,557 $ 351,260
 
Adjustments:
Additions to property, plant, equipment
and software capitalization (20,839 ) (17,647 ) (36,831 ) (35,358 )
Tax reform payments 46,700 - 46,700 -
Litigation settlement payment 15,400 - 15,400 -
Major facility renovations 1,801 - 1,801 -
       
Free Cash Flow - Adjusted Non-GAAP $ 143,778   $ 159,404   $ 303,627   $ 315,902  
     

(a) The Company defines free cash flow as net cash flow from operations
accounted for under GAAP less capital expenditures and software
capitalizations plus or minus any unusual and non recurring items. Free
cash flow is not a GAAP measurement and may not be comparable to free
cash flow reported by other companies.

 
Waters Corporation and Subsidiaries
Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial
Outlook
(In thousands, except per share data)
       
 
Three Months Ended Twelve Months Ended
September 29, 2018 December 31, 2018
Range Range
Projected Sales
 
Projected constant currency sales growth rate 4% - 6% 4% - 6%
 
Projected currency impact (2%) - (1%) 0% - 1%
       
Projected sales growth rate as reported 2% - 5% 4% - 7%
 
 
Projected Earnings Per Diluted Share Range Range
 
 
Projected GAAP earnings per diluted share $ 1.81 - $ 1.91 $ 7.81 - $ 7.96
Adjustments:
Purchased intangibles amortization $ 0.02 - $ 0.02 $ 0.07 - $ 0.07
Restructuring costs and certain other items $ - - $ - $ 0.02 - $ 0.02
Pension termination $ 0.01 - $ 0.01 $ 0.04 - $ 0.04
Litigation provision $ - - $ - $ (0.02 ) - $ (0.02 )
Stock award modification $ - - $ - $ 0.01 - $ 0.01
Tax reform $ - - $ - $ 0.05 - $ 0.05
Certain income tax items $ 0.01   - $ 0.01   $ 0.07   - $ 0.07  
Projected adjusted non-GAAP earnings per diluted share $ 1.85   - $ 1.95   $ 8.05   - $ 8.20  

 

Constant currency growth rates are a non-GAAP financial measure that
measures the change in net sales between current and prior year periods,
ignoring the impact of foreign currency exchange rates during the
current period. These amounts are estimated at the current foreign
currency exchange rates and based on the forecasted geographical sales
in local currency as well as an assessment of market conditions as of
today and may differ signficantly from actual results.

These forward-looking adustment estimates do not reflect future gains
and charges that are inherently difficult to predict and estimate due to
their unknown timing, effect and/or significance.

View Comments and Join the Discussion!